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Introduction
Gastric cancer is the fourth most common cancer and 
the second most common cause of cancer-related death 
in the world (Ferlay et al., 2015; Haghighi et al., 2016). 
Approximately two-thirds of these cancers occur in the 
developing countries in Eastern Europe, South America, 
and Asia (Chen et al., 2014). In Iran, gastric cancers are the 
most common cause of cancer deaths and their incidence 
are higher than the global average (Zamani et al., 2013).
Surgery is the only definitive cure for gastric cancer, 
but a significant proportion of these patients are at the 
advanced stage at the time of diagnosis, or more than 
half develop recurrence after surgery. Therefore palliative 
chemotherapy is now a well-known and effective method 
compared to other supportive treatments in patients with 
advanced gastric cancer (Huang et al., 1998; Zabaleta, 
2012).
The overall survival (OS) of advanced gastric cancer 
is very low; the median OS was 7.5 to 12 months after 
chemotherapy compared with 3 to 5 months in patients 
receiving supportive therapy. Although overall treatment 
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outcomes have not been satisfactory, chemotherapy has 
been associated with higher survival and better quality of 
life compared to supportive treatment (Casaretto et al., 
2006; Glimelius et al., 1997; Wagner et al., 2006; Wagner 
et al., 2010). In addition, meta-analysis studies have shown 
that combination therapy is also highly effective (Iwase et 
al., 2011; Koizumi et al., 2012; Kim et al., 2011) and the 
triple-drug regimen is much better than the single-drug or 
double-drug regimen (Koizumi et al., 2008; Van Cutsem 
et al., 2006).
Different chemotherapy regimens have been 
introduced for patients with advanced gastric cancer. 
Oxaliplatin plus 5-fluorouracil (5-FU) and leucoverin, 
as FOLFOX regimen, is widely used in the treatment of 
gastrointestinal cancers with 40-50% response rate and 
survival after treatment to be 10 to 12 months (Oh et al., 
2007). Docetaxel plus cisplatin plus 5-FU as the DCF 
regimen is the other commonly used regimen which has 
been associated with acceptable survival and better quality 
of life (Chen et al., 2013).
Despite the efficacy of DCF in progressive gastric 
cancer, studies have reported that the incidence of grade 
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3-4 chemotherapy related toxicities is higher than other 
combination regimens and is therefore not the standard 
treatment regimen in these patients (Roth et al., 2007; Van 
Cutsem et al., 2006). However, FOLFOX had acceptable 
anti tumor activity and tolerable toxicity profile in different 
treatment protocols and doses (Hacibekiroglu et al., 2015; 
Haghighi t al., 2016; Yeh et al., 2012; Zhang et al., 2012).
The aim of our study was to evaluate the efficacy of 
FOLFOX as the first line of treatment in patients with 
advanced gastric adenocarcinoma compared with mDCF.
Materials and Methods 
In this cross-sectional study, all patients between 18-80 
years old with advanced gastric adenocarcinoma (non-
resectable tumor) receiving FOLFOX-4 or modified DCF 
chemotherapy regimen during October 2015 and October 
2018 were included. Patients with previous history of 
chemotherapy or other malignancy, severe underlying or 
infectious disease, with brain metastasis or other causes of 
severe neuropathy were excluded. The ethics committee 
of Ardabil University of Medical Sciences have approved 
the study protocol (Approve no: ARUMS.REC.1396.209). 
In all patients, demographic and baseline data including 
age at the time of diagnosis, gender, clinical findings, 
disease stage and metastasis as well as demographic, 
physical exam, laboratory and imaging finings at the end 
of each chemotherapy cycles were recorded. 
Tumor was evaluated using CT studies every four 
cycles. Patients response to treatment was measured by 
RECIST criteria (Response Evaluation Criteria In Solid 
Tumors) using http://www.radiologytutor.com/index.php/
cases/oncol/139-recist. CT scan findings were compared 
before chemotherapy and after each period to define 
RECIST. 
Complete remission (CR) was defined as there was no 
sign of disease, Partial response (PR) is considered when 
at least 30 percent of tumor mass was reduced in imaging 
studies and there was no new lesion or findings regarding 
the disease progress. Progressive disease (PD) was noted if 
there was at least 20% increase in largest diameter of the 
lesion or occurrence of new lesion or metastasis. Stable 
disease was considered when the treatment response did 
not reach any criteria of complete or partial response and 
also is not progressive. Overall response rate (ORR) was 
the sum of PR and CR. 
Progress free survival (PFS) was the duration from 
the diagnosis of the disease till the recurrence or disease 
progress or the patient death. Those patients with no 
changes during the study period were excluded from this 
evaluation. 
The chemotherapy related complications including 
hematologic, gastrointestinal, neuropathy were recorded 
in both treatment groups. We also evaluated other 
drug-related complications.
Statistical analysis
All data were analyzed using the SPSS software 20 
(Statistical Package for the Social Sciences, SPSS Inc., 
Chicago, IL, U.S.A.). Results were presented as mean 
and standard deviation (SD) or frequency and percentage. 
Independent T test or Mann Whitney U, Chi square of 
Fischer’s exact tests were used to compare the findings 
between two regimens. P-values of <0.05 were considered 
significant. 
Results
In this study, 104 patients received chemotherapy 
including 47 with FOLFOX regimen and 57 with mDCF. 
There was no difference between groups regarding 
baseline findings (Table 1). 
Figure 1 is demonstrating the response rate between 
groups. mDCF compared to FOLFOX had more cases 
with stable disease and less progression, but there was 
no significant difference between groups (p=0.25). ORR 
was 46.98% in FOLFOX and 35.1% in mDCF, but the 
difference was not significant (p=0.22). 
Six patients (12.8%) in FOLFOX group and 10 patients 
(17.5%) in mDCF group died during the study period 
(p=0.5). The time between disease diagnosis and death 
in these patients were 8.33±1.03 months in FOLFOX vs. 
6.50±2.32 months in mDCF group (p=0.09). 
Overall survival (OS) in FOLFOX and mDCF groups 
were 12.61±4.05 and 13.50±5.94 months, respectively 
with no significant difference between groups. FOLFOX 
Figure 1. Response Rate between FAOLFOX and mDCF Groups
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(2020) reported that FOLFOX6 regimen with response 
rate of 50% is an effective treatment for gastric cancer. 
Bhat (2018) also observed that the leucoverin, Oxaliplatin 
and 5-FU regimen (exactly FOLFOX) has adequate 
response in advanced gastric cancer patients. 
In a meta-analysis, Patients with FolFOx-4 regimen 
had 12 and 6.7 months OS and PFS respectively, equal 
to some studies. Chen and colleagues (2013) concluded 
that the DCF regimen increases PR levels and reduced 
disease progression. Wang et al. (2016) reported ORR of 
48.7% following treatment with DCF in Chinese patients.
Hacibekiroglu et al., (2015) reported rather similar 
efficacy for FOLFOX-6 and DCF in advanced gastric 
cancers (OR of 37% and 40.3%, respectively). Kim et al., 
(2011) also noted that both FOLFOX and DCF regimens 
have similar improvement rate. Also, in our study both 
regimens have relatively equal efficacy.
In the present study, FOLFOX-4 regimen had OS of 
12 months and PFS of 6.7 months, with OS and PFS equal 
to some studies (Haghighi et al., 2013; Liu et al., 2008; 
Yeh et al., 2012). For FOLFOX-4 regimen, Haghighi et 
al., (2013) reported OS of 11.9 and PFS of 7.3; the mean 
OS in the study of Liu et al., (2008) was 10 months 11.9 
months in Yeh et al., study (2012). However, Baek et al., 
(2011) reported lower rate of OS and PFS (9.3 and 4.9 
months, respectively). 
In the current study, Mortality was seen in 12.8% and 
17.5% of FOLFOX-4 and modified DCF groups. There 
was no significant difference between two regimens 
regarding PFS and OS rate, while the PFS was lower in 
FOLFOX group. 
Similar to our study, Hacibekiroglu et al., (2015) also 
found that the both FOLFOX and DCF had relatively 
similar survival rates. However, Kim et al., (2011) reported 
shorted duration of disease progression for DCF compared 
to FOLFOX (4 vs. 15 months) with longer OS (48 vs. 
compared to mDCF groups had shorter PFS with no 
significant difference between groups (6.79±2.18 vs. 
7.97±3.14, p=0.1). 
Chemotherapy related toxicities are demonstrated 
in Table 2. Hematologic complications including 
neutropenia, fever and neutropenia and thrombocytopenia 
were significantly higher in mDCF compared to FOLFOX 
group. mDCF compared to FOLFOX regimen had 
significantly more cases with post-chemotherapy nausea 
and vomiting, creatinine rise, hair loss and facial changes 
(in all patients) and stomatitis. Neuropathy occurred 
in both groups with significantly higher incidence in 
FOLFOX compared to mDCF regimen. Most cases of 
neuropathy in both groups were grade I and II.  
Discussion
In this retrospective cross-sectional study, we 
evaluated the outcome of patients with advanced gastric 
adenocarcinoma following treatment with FOLFOX or 
mDCF regimens. 
The FOLFOX group had a relatively equal CR rate, 
higher PR, greater disease progression and lower stable 
disease compared with mDCF. Also, the ORR between 
the two groups was not statistically significant, despite 
being higher in the FOLFOX group.
Haghighi and colleagues (2016) in their study of 
elderly patients with advanced gastric cancer treated with 
FOLFOX-4, observed ORR of 72.6% with stable disease 
in 13%. In another study of elderly patients, Liu et al., 
(2008) observed that treatment with FOLFOX-4 was 
associated with an ORR of 52.5%. In the study of Yeh et 
al., (2012) the OR was 41.1%, the disease was stable in 
26%, and progression occurred in 32.9%. In the study of 
Baek et al., (2011) FOLFOX regimen showed the lowest 
CR (2.4%) and PR (23.8%) in 24 patients with advanced 
gastric cancer compared to other studies, while disease 
progression was 30.9%. The response rate in different 
studies varied between 26 and 72% depending on the study 
location, individual characteristics, and time of diagnosis. 
However, all studies indicate the acceptable efficacy of 




Age (years) 65.87±12.74 63.07±9.27 0.19
Gender
   Male 33 (70.2%) 46 (80.7%) 0.21
   Female 14 (29.8%) 11 (19.35)
Stage
   III 15 (31.9%) 20 (35.1%) 0.73
   IV 32 (68.1%) 37 (64.9%)
Metastasis
   Liver 12 (25.5%) 17 (29.8%) 0.99
   Abdomen and peritoneum 10 (21.3%) 7 (12.3%)
   Lung 3 (6.4%) 2 (3.5%)
   More than one Organ 7 (14.9%) 11 (19.3%)





Hematologic complications 12 (25.5%) 41 (71.95) <0.001
Neutropenia 9 (19.1%) 37 (64.9%) <0.001
Fever and neutropenia 2 (4.3%) 19 (33.3%) <0.001
Thrombocytopenia 5 (10.6%) 19 (33.3%) 0.006
Gastrointestinal complications 19 (40.4%) 37 (64.9%) 0.01
Diarrhea 5 (10.6%) 19 (33.3%) 0.006
Nausea 12 (25.5%) 35 (61.4%) <0.001
Vomiting 9 (19.1%) 29 (50.9%) <0.001
Increase in liver enzymes 2 (4.3%) 8 (14%) 0.09
Creatinine rise 5 (10.6%) 15 (26.3%) 0.04
Stomatitis 1 (2.1%) 20 (35.1%) <0.001
Hair loss 2 (4.3%) 57 (100%) <0.001
Neuropathy 27 (57.4%) 9 (15.8%) <0.001
Neuropathy grade
     I 14 (29.8%) 6 (10.5%) <0.001
     II 10 (21.3%) 3 (5.3%)
     III 2 (4.3%) 0
     IV 1 (2.1%) 0
Table 2. Chemotherapy Related Toxicities between 
FOLFOX and mDCF Groups
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37 months); however, there was no significant statistical 
difference between the two regimens. However, Liu et al., 
(2018) observed that DOF regimen (Oxaliplatin instead 
of cisplatin) compared to FOLFOX regimen was more 
effective in advanced gastric cancer patients.  
Chemotherapy-related toxicities are one of the causes 
that limit the use of different chemotherapy regimens. 
Therefore, researchers are trying to introduce regimens 
that have the least or acceptable toxicity with higher 
efficiency. The DCF regimen has higher rate of grade 3-4 
toxicities than other therapies and so has limited its use 
(Roth et al., 2007; Van Cutsem et al., 2006). 
In our study, hematologic and gastrointestinal 
complications were significantly higher in modified DCF, 
while peripheral neuropathy was significantly higher in 
FOLFOX-4. In other studies, the FOLFOX regimen was 
more acceptable due to its lower chemotherapy-related 
toxicities. Haghighi et al., (2016) reported only one case 
of grade 3 neuropathy in FOLFOX group.
Similar to the present study, Hacibekiroglu et al., 
(2015) reported higher hematologic and gastrointestinal 
toxicities in DCF compared to FOLFOX regimen. 
Similarly, Kim et al., (2011) stated that mucositis grade 
3-4 and leukopenia were more frequent in patients treated 
with DCF. Unlike these findings, Liu et al., (2018) 
observed that both DOF and FOLFOX regimen have 
acceptable toxicities comparable with each other, but in 
elder patients, DOF has significantly more neuropathy. 
Stomatitis is another chemotherapy related 
complication which was significantly higher in mDCF 
compared to FOLFOX. Similar results were reported by 
Wang et al., (2014), while Hacibekiroglu et al., (2015) did 
not find significant difference in stomatitis rate between 
groups. Salehifar et al., (2019) also find no significant 
difference between two regimen in stomatitis, visual 
change and skin reactions. 
Another notable finding was hair loss in 100% of 
mDCF patients, which was seen in only 4.3% of FOLFOX 
patients. Bhat (2018) also reported less hair loss in similar 
FOLFOX regimen compared to others. This hair loss and 
change in the appearance can have a significant impact on 
the morale and cause depression in these patients. 
Mitani et al., (2020) also indicated that FOLOFX6 has 
acceptable toxicity for chemotherapy-refractory advanced 
gastric cancer. Given the sum of the side effects of the 
treatment and the resulting toxicities, a treatment should 
be chosen that is well-tolerated with lower complications.
In conclusion, the results of current study showed 
that in patients with advanced gastric adenocarcinoma, 
FOLFOX regimen compared to mDCF regimen have 
similar ORR, OS and PFS. Toxicity rate are also lower 
in FOLFOX group, thus it seems a better regimen for 
chemotherapy.
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